EWTX

Edgewise Therapeutics, Inc.

Healthcare
Biotechnology
$4.78B market cap

Forecast run · Sep 14, 2026Upside rank 318 of 3,136

Model Signal

ForecastQ Daily Probabilities

61.4%

55.0%

36.4%

Analyst Consensus

Recommendation2.18/5 Buy

Last price$44.40

Price target$51.90

Implied move+16.9%

Analysts11

ForecastQ Portfolios

EWTX is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.